ST. LOUIS, March 12, 2019 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2018. “2018 was an extremely active year at Stereotaxis with progress […]
Financial
Neovasc Announces Agreements to Exchange Outstanding Warrants for Shares
VANCOUVER, March 12, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN) announced today that it has entered into exchange agreements (“Exchange Agreements”) with the holders (“Holders”) of all of its outstanding Series A common share purchase warrants and Series E common share purchase warrants (collectively, the “Warrants”) issued pursuant […]
Zynex Expands Corporate Headquarters to Accommodate Growth
ENGLEWOOD, Colo., March 12, 2019 /PRNewswire/ — Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it has signed an addendum to its corporate headquarters building lease expanding the footprint to 63,000 square feet, […]
William T. Abraham, MD, joins V-Wave as Chief Medical Officer
CAESAREA, Israel, March 12, 2019 /PRNewswire/ — V-Wave Ltd., an early stage medtech company developing an implantable interatrial shunt device for treating advanced heart failure (HF) and pulmonary arterial hypertension (PAH), announced today that renowned heart failure cardiologist, William T. Abraham, MD, is joining V-Wave as Chief Medical Officer. Dr. Abraham makes this move […]
Edwards Lifesciences Announces Strategic Investments
IRVINE, Calif., March 11, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced two strategic transactions involving companies with structural heart disease technologies. Edwards has invested $35 million in an exclusive right to acquire Corvia Medical, Inc., the developer of […]
ShockWave Announces Pricing of Initial Public Offering
SANTA CLARA, Calif., March 06, 2019 (GLOBE NEWSWIRE) — ShockWave Medical, Inc. (“ShockWave”) today announced the pricing of its initial public offering of 5,700,000 shares of its common stock at a price to the public of $17.00 per share. The shares are expected to begin trading on the Nasdaq Global […]
DalCor Announces Appointment of Paul R. Fonteyne to Chairman of the Board
LONDON and MONTREAL, March 07, 2019 (GLOBE NEWSWIRE) — DalCor Pharmaceuticals today announced the appointment of Paul R. Fonteyne to Chairman of the Board effective February 27, 2019. “I am delighted to pass the baton to Paul Fonteyne who will assume the Chairmanship of DalCor,” said Robert McNeil, Ph.D., Chairman, […]
Avinger Provides Fourth Quarter and Full Year 2018 Shareholder Update
REDWOOD CITY, Calif., March 06, 2019 (GLOBE NEWSWIRE) — Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported results for the fourth quarter and full year ended December […]
SynCardia Announces Promotion of Don Webber to CEO
TUCSON, Ariz., March 7, 2019 /PRNewswire/ — SynCardia Systems, LLC, manufacturer of the world’s only clinically-proven and commercially approved total artificial heart, is pleased to announce that Don Webber has been named Chief Executive Officer (CEO). Mr. Webber joined SynCardia in 2018 as Chief Operating Officer (COO), leading Manufacturing Operations and Engineering, Quality and Supply […]
PLx Pharma Inc. Reports Fourth Quarter 2018 Results
HOUSTON, March 08, 2019 (GLOBE NEWSWIRE) — PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, Vazalore™ 325 mg and Vazalore™ 81 mg (referred to together […]